adocia.comCrawled Nov 22, 2026
Drugs for long-term therapy typically need frequent administrations which can be a burden to patients and a barrier to effective therapy.
Adocia develops innovative products and demonstrates their proof of concept to license them to pharmaceutical partners.
Adocia develops innovative formulations of approved peptides and new cellular therapy approaches for treating diabetes and obesity.
The Adocia Human Resources policy aims to build and develop an excellent, international, highly qualified and multidisciplinary team, to meet complex scientific and technological objectives, in order to improve patients’ health.
Adocia laboratories and offices are located on a single site in Lyon, which encourages communication and social ties between the teams.
He joined Sangamo Therapeutics on the back of the acquisition by the latter of TxCell SA, a CAR-Treg company he was the CEO of. Stéphane is a seasoned biotech professional with over 25 years of leadership experience across corporate finance, strategy and business development.
Adocia breakthrough innovations are supported by a medical advisory board including some of the most distinguished key opinion leaders
Adocia discovers and develops therapeutic solutions for metabolic diseases like diabetes and obesity.
Adocia has built a unique expertise in diabetes and obesity. Over the years, Adocia has consolidated a rich specialty product portfolio which is one of the broadest and most differentiated for the treatment of metabolic diseases.
Adocia discovers and develops therapeutic solutions for metabolic diseases.
Adocia is a French biotech company founded in 2005 by Gérard, Olivier, and Rémi Soula.
Adocia is a clinical-stage biotechnology company specializing in innovative treatments for diabetes and obesity.